Menu Search
Equities

Embla Medical hf

0FIW:LSE

Embla Medical hf

Actions
  • Price (DKK)34.70
  • Today's Change34.70 / --
  • Shares traded4.00
  • 1 Year change+26.41%
  • Beta--
Data delayed at least 20 minutes, as of Oct 31 2024 11:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Embla Medical hf grew revenues 9.33% from 718.65m to 785.68m. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 37.34% net income growth from 42.51m to 58.39m.
Gross margin62.02%
Net profit margin8.25%
Operating margin12.60%
Return on assets4.75%
Return on equity9.47%
Return on investment5.51%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Embla Medical hf fell by 3.98m. However, the company earned 94.32m from its operations for a Cash Flow Margin of 12.01%. In addition the company used 57.15m on investing activities and also paid 40.96m in financing cash flows.
Cash flow per share2.04
Price/Cash flow per share17.76
Book value per share13.06
Tangible book value per share-2.08
More ▼

Balance sheet in USDView more

Embla Medical hf has a Debt to Total Capital ratio of 40.74%, a lower figure than the previous year's 60.39%.
Current ratio1.99
Quick ratio1.26
Total debt/total equity0.69
Total debt/total capital0.4074
More ▼

Growth rates in USD

SmartText is unavailable
Div yield(5 year avg)0.07%
Div growth rate (5 year)--
Payout ratio (TTM)0.00%
EPS growth(5 years)-5.77
EPS (TTM) vs
TTM 1 year ago		30.03
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.